Schistosoma mansoni Infections Are Associated With Fecal Calprotectin Markers of Gut Inflammation After Accounting for HIV, Hepatitis B, and Malaria.
Government health care worker training needs for schistosomiasis morbidity management
<i>Schistosoma mansoni</i>
infections are associated with hepatosplenic organometry within the context of repeated praziquantel treatment and co-endemic infections of malaria, hepatitis B, and HIV: a population-based study in rural Uganda
Individual and spatial heterogeneity of praziquantel efficacy against
<i>Schistosoma mansoni</i>
within the context of repeated mass drug administration
Safety and efficacy of praziquantel 40 mg/kg versus 80 mg/kg in preschool-aged children with intestinal schistosomiasis in Uganda: a 2 × 2 factorial, double-blind, placebo-controlled, phase 2 randomised trial
Interpretable machine learning and signal processing for automated reading and quality control of lateral flow tests for schistosomiasis
Influence of <i>Schistosoma mansoni</i> infection on faecal calprotectin in the context of HIV, hepatitis B, and malaria co-infections
Co-occurrence of alcohol use and <i>Schistosoma mansoni</i> infection: prevalence, patterns, and risk factors in rural Uganda
Bayesian machine learning enables discovery of risk factors for hepatosplenic multimorbidity related to schistosomiasis
An artificial intelligence-powered digital pathology platform to support large-scale deworming programs against soil-transmitted helminthiasis and intestinal schistosomiasis in resource-limited settings
HIV testing and prevalence in fishing communities in rural Uganda: a cross-sectional study of 3197 individuals within SchistoTrack
Non-linear age dynamics of malaria infection and fine-scale environmental exposure in rural Uganda
Medical, socioeconomic, and geographic disparities in primary health care access and utilization: A population-based study of 8038 individuals aged one year and older in rural Uganda
Human mobility-based spatial decay models of unsafe and safe water usage in rural Uganda
Maintaining community-based cohorts in sub-Saharan Africa: An evaluation of participant attrition in SchistoTrack
Current <i>Schistosoma mansoni</i> exposure and infection have distinct determinants: a data-driven population-based study in rural Uganda
Multimorbidity representation via graph learning: A population-based study on hepatosplenic conditions in schistosomiasis-endemic areas of rural Uganda
Relationships Between <i>Schistosoma mansoni</i> Infection Intensity and Nutritional Status and Anemia Among Preschool-aged Children in Uganda
Establishing a single-sex controlled human <i>Schistosoma mansoni</i> infection model for Uganda: protocol for safety and dose-finding trial
The epidemiology of periportal fibrosis and relevance of current<i>Schistosoma mansoni</i>infection: a population-based, cross-sectional study
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis
The praziquantel in preschoolers (PIP) trial: study protocol for a phase II PK/PD-driven randomised controlled trial of praziquantel in children under 4 years of age
Praziquantel and Upper Gastrointestinal Bleeding in Hepatic Schistosomiasis: A Quasi-Experimental Study.
Does Intensive Treatment Select for Praziquantel Resistance in High-Transmission Settings? Parasitological Trends and Treatment Efficacy Within a Cluster-Randomized Trial
Anthelminthic treatment receipt and its predictors in Lake Victoria fishing communities, Uganda: Intervention coverage results from the LaVIISWA cluster randomised trial.
Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda
Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda
Schistosomiasis in Africa: Improving strategies for long-term and sustainable morbidity control
Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy
Expanding Praziquantel (PZQ) Access beyond Mass Drug Administration Programs: Paving a Way Forward for a Pediatric PZQ Formulation for Schistosomiasis